GF
GLMD icon

Gerry Farber’s Galmed Pharmaceuticals GLMD Stock Holding History

Gerry Farber’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-289
Closed -$506K – 42
2014
Q2 		$506K Hold
289
– – 0.53% 50
2014
Q1 		$596K Buy
+289
New +$677K 1.03% 32

Other funds holding GLMD

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gerry Farber's GLMD Position: Q3 2014 in Review

Gerry Farber sold out of Galmed Pharmaceuticals (GLMD) in Q3 2014, closing a stake of 289 shares — an estimated $506K sold.

Gerry Farber first reported a position in GLMD in Q1 2014 and held it in 2 quarters. The position peaked at $596K in Q1 2014. 19 funds tracked by Wall St. Rank hold GLMD as of Q3 2014.

  • Gerry Farber reported no remaining Galmed Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Gerry Farber sold 289 Galmed Pharmaceuticals shares in Q3 2014, an estimated $506K.
  • Gerry Farber first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Gerry Farber's Galmed Pharmaceuticals position peaked at $596K in Q1 2014.
  • 19 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2014.

Based on Gerry Farber's 13F filing for Q3 2014, filed 17 Oct 2014.